Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report

RATIONALE: Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death worldwide. Its poor prognosis is due to the high invasiveness of the disease and limited efficacy of available treatments. PATIENT CONCERNS: We reported an HCC patient who developed lung metastases 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Hong, Zhang, Chunyan, Yang, Xi, Yi, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417557/
https://www.ncbi.nlm.nih.gov/pubmed/30855507
http://dx.doi.org/10.1097/MD.0000000000014823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417557/
https://www.ncbi.nlm.nih.gov/pubmed/30855507
http://dx.doi.org/10.1097/MD.0000000000014823

Ejemplares similares